Apr 15, 2021 · Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects.
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
... investor relations activities. He also served as Chief Medical Officer at GenVec and as Senior Director of Clinical Science at Medarex. Prior to joining the ...
May 25, 2022 · Genocea Biosciences (GNCA) stock is on the move Wednesday after the bioscience company revealed its shutting down and delisting shares.
Missing: relations | Show results with:relations
Get the latest insights on Genocea Biosciences Inc Ordinary Shares (GNCA) with press releases and corporate news to help you in your trading and investing ...
People also ask
What happened to Genocea Biosciences?
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases.
Common stock, $0.001 par value per share, GNCA. Nasdaq Capital Market. Indicate by check mark whether the registrant is an emerging growth company as defined ...
Missing: investor relations
Investor Contact. Gail M. Peck, Chief Financial Officer Erin Drabek, Director of Investor Relations InvestorResources@arcosa.com. ADVISIRY Partners David Gold
Missing: gnca | Show results with:gnca
Mar 19, 2024 · Genocea Biosciences (GNCA) Investor Presentation - Slideshow · SA TranscriptsThu, Apr. 15, 2021. Genocea Biosciences, Inc. (GNCA) CEO Chip ...
Missing: relations | Show results with:relations
Genocea Biosciences (GNCA) insider trading. Corporate insiders sold or buy shares in the last 3 months. See the highest value insider transactions.
Missing: relations | Show results with:relations